SharesGrow 7-Criteria Score
All 7 criteria scored · valuation-related highlighted on this page
Sartorius Stedim Biotech S.A. (SRTOY) 当前追踪市盈率 (P/E) 为 833.5. 追踪盈利收益率为 0.12%. PEG 18.77.
本页证实的标准:
- VALUE (15/100, 未通过) — 追踪市盈率远高于标普500平均值约25，表明估值偏高 (P/E 833.5); 追踪盈利收益率低于10年期国债收益率（约4.3%），意味着债券提供更好的回报 (EY 0.12%); PEG > 2.0 意味着即使考虑增长，该股票仍然昂贵 (PEG 18.77).
- PEG 比率 18.77 — 高于2.0表明相对于盈利增长偏贵。
- 追踪盈利收益率 0.12% — 低于债券收益率 — 投资者为预期增长而非当前盈利支付溢价。
SharesGrow 综合评分： 44/100 其中 1/7 项标准通过。
SharesGrow 7-Criteria Score
✗
价值
15/100
Price-to-Earnings & upside
Proven by this page
~
健康
50/100
Debt-to-Equity & liquidity
→ Health
估值概览 — SRTOY
估值倍数
P/E (TTM)833.5
前瞻 P/EN/A
PEG 比率18.77
前瞻 PEGN/A
P/B 比率0.00
P/S 比率73.96
EV/EBITDA0.0
每股数据
EPS (TTM)$0.03
每股账面价值$0.00
每股营收$0.29
每股自由现金流$0.00
收益率与内在价值
盈利收益率0.12%
股息收益率0.00%
P/E Ratio & Earnings Yield
每股收益 (EPS) 历史
| Year |
EPS（稀释） |
营收 |
净利润 |
净利润率 |
| 2016 |
$0.02 |
$1.05B |
$153.68M |
14.6% |
| 2017 |
$0.02 |
$1.08B |
$161.09M |
14.9% |
| 2018 |
$0.02 |
$1.21B |
$208.05M |
17.2% |
| 2019 |
$0.03 |
$1.44B |
$234.57M |
16.3% |
| 2020 |
$0.04 |
$1.91B |
$335.93M |
17.6% |
| 2021 |
$0.05 |
$2.89B |
$414.4M |
14.4% |
| 2022 |
$0.10 |
$3.49B |
$876.1M |
25.1% |
| 2023 |
$0.03 |
$2.78B |
$309.7M |
11.2% |
| 2024 |
$0.02 |
$2.78B |
$175.1M |
6.3% |
| 2025 |
$0.03 |
$2.85B |
$255.12M |
9% |
